COMPARISON / 05
Sermorelin vs Tesamorelin: GHRH Analogs in Body-Composition Research
Same receptor, different build. The native short-acting fragment beside the stabilized, longer-lasting analog — what each is, what each was studied for, and where the body-composition evidence actually lives.
The short version
Sermorelin vs tesamorelin is a comparison of two molecules that pull the same lever — the GHRH receptor (the pituitary's "make growth hormone" switch) — but are built differently. Sermorelin is the short native fragment, GHRH(1-29), cleared from blood in minutes. Tesamorelin is a stabilized, longer-lasting GHRH analog that resists the enzymes that chew up the native peptide. The practical difference shows up in the evidence: the strongest belly-fat (visceral-fat) data in this drug class come from tesamorelin trials, while sermorelin's firmest record is in childhood growth and the adult growth-hormone axis. This page keeps those lanes separate so a tesamorelin finding is never mistaken for a sermorelin one.
Two GHRH analogs, one receptor
Both sermorelin and tesamorelin are growth hormone-releasing hormone analogs that act on the same GHRH receptor on pituitary somatotrophs, stimulating the body's own GH release with feedback preserved [13]. They are members of the same mechanistic family, not rivals with different targets. Each works upstream — a trigger for the gland rather than a supply of hormone — so both leave somatostatin and IGF-1 feedback intact and both preserve the natural pulsatile pattern of GH secretion [4].
The difference is structural. Sermorelin is the amidated native 1-29 fragment of GHRH — the shortest fully active piece, and a short-half-life molecule by nature [3]. Tesamorelin is a stabilized synthetic GHRH analog engineered for protease resistance and a longer functional effect, which is what made it viable as a once-daily approved therapy in its indication. Put simply: the receptor and the downstream pulse are shared; the molecule's durability in the body is not.
Pharmacokinetics: short native fragment vs stabilized analog
The pharmacokinetic contrast is the practical heart of sermorelin vs tesamorelin. Sermorelin clears from plasma in about 10-12 minutes, though a single dose still elevates GH for roughly 3 hours [3]. That short plasma life is typical of small unprotected peptides, which are cleaved quickly by circulating peptidases. Its brevity is the reason the field engineered longer-acting analogs in the first place — see sermorelin half-life.
Tesamorelin's stabilization gives it a longer functional window, supporting sustained daily dosing in trials measuring weeks-to-months endpoints [6][9]. The two molecules therefore differ less in what they do per pulse than in how durably they keep doing it. Same receptor, same feedback-preserving mechanism; a meaningfully longer effective duration on the tesamorelin side. This is the same engineering logic that produced the other long-acting GHRH analogs — a D-Ala2-type substitution to resist enzymatic cleavage, or an albumin-binding complex to tether the peptide to a long-circulating carrier.
Where the body-composition evidence lives
This is the distinction that matters most for honest reading. The drug-class body-composition evidence is concentrated on the tesamorelin side. In HIV-infected patients with abdominal fat accumulation, tesamorelin significantly reduced visceral adipose tissue versus placebo [9]; a randomized trial in HIV-infected men with lipodystrophy evaluated the same axis on fat distribution [10]; and the 152-adult GHRH-analog trial reported IGF-1 +117% and percent body fat -7.4% over 20 weeks [6]. Those are specific, randomized, placebo-controlled measurements — but they belong to the stabilized analog, not to GHRH(1-29).
Sermorelin's own firmest evidence is in childhood growth — first-year height velocity from about 4.1 to 7-8 cm/year [1], with the growth-velocity signal extending even to short children with normal GH secretion [8] — and in the adult GH/IGF-1 axis, where it reversed age-related declines in older men [2]. The mechanistic link between the two records is the GH/IGF-1 axis itself: visceral fat is not a passive bystander to GH secretion. In 47 men studied under combined GHRH and GHRP-2, abdominal visceral fat, IGF-1 and IGFBP-3 together explained 60% of the variability in the GH response, visceral fat negatively associated [7]. So the body-composition story is biologically continuous across the class. But when body-composition claims are made for "sermorelin" specifically, they are usually leaning on the tesamorelin trial record. That borrowing should be stated, not blurred — which is the entire reason this comparison page keeps the two molecules in separate columns.
What each was studied for
The two molecules carry different research records, and conflating them is the most common error in popular summaries. Sermorelin's strongest evidence is developmental and adult-axis: accelerated growth in growth-hormone-deficient children [1], growth-velocity gains in short children with normal GH secretion [8], and reversal of the age-related GH/IGF-1 decline in older men [2].
Tesamorelin's record is built around body composition. Its visceral-fat reduction versus placebo in HIV-associated fat accumulation is the anchor finding [9]; a randomized trial in HIV-infected men with lipodystrophy examined the same axis [10]; and the 152-adult GHRH-analog trial that reported IGF-1 +117% and percent body fat -7.4% over 20 weeks used the tesamorelin-class molecule, not sermorelin [6]. So when a body-composition claim is attached to "sermorelin," check whether the underlying study actually used GHRH(1-29) or the stabilized analog. Usually it is the latter.
Regulatory framing: both honestly stated
Both molecules have specific, often-misstated regulatory histories. Sermorelin was FDA-approved for pediatric growth-hormone deficiency (NDA 020443) and withdrawn from the US market in 2008 for commercial reasons — not safety or efficacy — and is now compounded as a Category 1 bulk drug substance under FDA's Section 503A framework [5]. Tesamorelin is a currently FDA-approved drug, but approved only for a single indication: HIV-associated lipodystrophy. Neither molecule is approved as an anti-aging or general weight-loss therapy, and the body-composition findings above sit outside both molecules' approved-or-formerly-approved uses. Both are prohibited in sport under the WADA growth-hormone-secretagogue category (S2), and dedicated detection methods for GHRH analogs exist. This site describes the research record only and gives no human dosing for either compound.